GLAXOSMITHKLINE PLC Form 6-K July 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 17 July 2017

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

	Details of PDMR/person closely associated with them ('PCA') Name Ms E Walmsley			
b)	Position/status	Chief Ex	ecutive Officer	
c) 2.	Initial notification/ amendment Details of the issuer, emission allowance		otification participant, auction platform,	
	auctioneer or auction monitor			
-	Name LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793		
3.		e repeated for (i) each type of instrument; te; and (iv) each place where transaction(s)		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')		
b)	Nature of the transaction	Increase Shares for dividend 2017 on Company Plan.	in notional interest in Ordinary ollowing the re-investment of s paid to shareholders on 13 July Ordinary Shares held in the y's 2009 Deferred Annual Bonus Volume(s) 70.538 (personal contribution)	
c)	Price(s) and volume(s)	£16.18 £16.18 £16.18 £16.18 £16.18 £16.18 £16.18 £16.18 £16.18	174.682 (personal contribution) 190.188 (personal contribution) 70.538(personal contribution) 174.669 (personal contribution) 190.176 (personal contribution) 70.538 (matching shares) 174.682 (matching shares) 190.188 (matching shares) 70.538 (matching shares) 174.669 (matching shares)	

£16.18 190.176 (matching shares)

£16.18 51.658 (matching shares)

4)	Aggregated information		
d)	Aggregated volume Price	1,741.58 £16.18	2
e)	Date of the transaction	2017-07	-14
f)	Place of the transaction	n/a	
	Details of PDMR/person closely associa Name	ted with t	
		_	t, Global Manufacturing &
D)	Position/status	Supply	•
c)	Initial notification/ amendment	Initial no	otification
2.	Details of the issuer, emission allowance market participant, auction platform		
	Name		nithKline plc
b)	LEI Details of the transportion(s), section to be	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instru (ii) each type of transaction; (iii) each date; and (iv) each place where transactions been conducted		
		Ordinary shares of 25 pence each	
a)	Description of the financial instrument	('Ordina	ry Shares')
b)	Nature of the transaction	ISIN: GB0009252882 Increase in notional interest in Ordinar Shares following the re-investment of dividends paid to shareholders on 13 J 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bor Plan.	
			Volume(s) 51.658 (personal contribution)
		210.10	51.056 (personal contribution)
		£16.18	118.682 (personal contribution)
		£16.18	99.029 (personal contribution)
		£16.18	51.658 (personal contribution)
c)	Price(s) and volume(s)	£16.18	99.017 (personal contribution)
		£16.18	51.658 (matching shares)
		£16.18	118.682 (matching shares)

£16.18 99.017 (matching contribution)

Aggregated information

d)

840.088 Aggregated volume Price £16.18 e) Date of the transaction 2017-07-14

Place of the transaction f)

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Debruyne

b) Position/status President, Global Vaccines

Initial notification/

Initial notification amendment

Details of the issuer, emission allowance market participant, auction platform,

auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument;

3. (ii) each type of transaction; (iii) each date; and (iv) each place where

transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the

Company's 2009 Deferred Annual Bonus

Plan.

Price(s) Volume(s)

£16.18 166.446 (personal contribution)

£16.18 166.433 (personal contribution) c) Price(s) and volume(s)

£16.18 166.446 (matching shares)

£16.18 166.433 (matching shares)

Aggregated information

b) Nature of the transaction

d)

665.758 Aggregated volume Price £16.18 e) Date of the transaction 2017-07-14

Place of the transaction f) n/a

1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr S Dingemans Chief Financial Officer b) Position/status Initial notification/ Initial notification amendment Details of the issuer, emission allowance market participant, auction platform, 2. auctioneer or auction monitor a) Name GlaxoSmithKline plc 5493000HZTVUYLO1D793 b) LEI Details of the transaction(s): section to be repeated for (i) each type of instrument; 3. (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July b) Nature of the transaction 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. Price(s) Volume(s) £16.18 98.527 (personal contribution) £16.18 230.682 (personal contribution) £16.18 172.780 personal contribution) £16.18 98.514 (personal contribution) £16.18 230.669 (personal contribution) £16.18 172.780 (personal contribution) c) Price(s) and volume(s) £16.18 98.527 (matching shares) £16.18 230.682 (matching shares) £16.18 172.780 (matching shares) £16.18 98.514 (matching shares) £16.18 230.669 (matching shares) £16.18 172.780 (matching shares) d) Aggregated information Aggregated volume Price 2,007.904

£16.18

e) Date of the transaction 2017-07-14 Place of the transaction n/a 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr N Hirons b) Position/status SVP, Global Ethics & Compliance Initial notification/ Initial notification amendment Details of the issuer, emission allowance market participant, auction platform, 2. auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of instrument; 3. (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 b) Nature of the transaction July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. Price(s) Volume(s) £16.18 36.169 (personal contribution) £16.18 85.292 (personal contribution) £16.18 62.593 (personal contribution) £16.18 36.169 (personal contribution) £16.18 85.292 (personal contribution) £16.18 62.582 (personal contribution) c) Price(s) and volume(s) £16.18 36.169 (matching shares) £16.18 85.292 (matching shares) £16.18 62.593 (matching shares) £16.18 36.169 (matching shares) £16.18 85.292 (matching shares)

£16.18 62.582 (matching shares)

£16.18 201.553 (matching shares)

£16.18 173.006 (matching shares)

£16.18 201.553 (matching shares)

	Aggregated information			
d)	A gama gotad valuma Drias	736.194		
	Aggregated volume Price	£16.18		
e)	Date of the transaction Place of the transaction	2017-07	-14	
f)	riace of the transaction	n/a		
1	Details of PDMR/person closely associa	tad with t	ham ('DCA')	
	Name	Mr S A		
	Position/status		t, Global Pharmaceuticals	
c)	Initial notification/ amendment	Initial no	otification	
2.	Details of the issuer, emission allowance auctioneer or auction monitor	market p	participant, auction platform,	
a)	Name	GlaxoSn	nithKline plc	
b)	LEI	5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
		Ordinary	shares of 25 pence each	
a)	Description of the financial instrument		ry Shares')	
b)	Nature of the transaction	ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus		
		Plan.	•	
		Price(s) £16.18	Volume(s) 170.501 (personal contribution)	
		£16.18	201.553 (personal contribution)	
		£16.18	173.006 personal contribution)	
		£16.18	201.553 (personal contribution)	
- \	Drive(a) and values (a)	£16.18	172.994 (personal contribution)	
c)	Price(s) and volume(s)	£16.18	170.501 (matching shares)	

£16.18 172.994 (matching shares)

Aggregated information

d)

Aggregated volume Price 1,839.214 £16.18 e) Date of the transaction 2017-07-14

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara

b) Position/status CEO, GSK Consumer Healthcare

Initial notification/

Initial notification

amendment

Initial notification

2 Details of the issuer, emission allowance market participant, auction platform,

auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument;

3. (ii) each type of transaction; (iii) each date; and (iv) each place where

transaction(s) has been conducted

American Depositary Shares ('ADSs')

a) Description of the financial instrument

ISIN: US37733W1053

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 July 2017 on

b) Nature of the transaction paid to shareholders on 13 July 2017 on

ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s) Volume(s)

\$42.50 70.929 (personal contribution)

c) Price(s) and volume(s)

\$42.50 70.929 (matching shares)

Aggregated information

d)

Aggregated volume Price

Aggregated volume Price

141.858

\$42.50

e) Date of the transaction

2017-07-14

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Nameb) Position/statusMr D S RedfernChief Strategy Officer

Initial notification/
Initial notification

amendment

Details of the issuer, emission allowance market participant, auction platform,

auctioneer or auction monitor

a) Name GlaxoSmithKline plc

5493000HZTVUYLO1D793 b) LEI Details of the transaction(s): section to be repeated for (i) each type of instrument; 3. (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July b) Nature of the transaction 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan. Price(s) Volume(s) £16.18 57.960 (personal contribution) £16.18 108.550 (personal contribution) £16.18 78.775 (personal contribution) £16.18 57.960 (personal contribution) £16.18 108.550 (personal contribution) £16.18 78.763 (personal contribution) c) Price(s) and volume(s) £16.18 57.960 (matching shares) £16.18 108.550 (matching shares) £16.18 78.775 (matching shares) £16.18 57.960 (matching shares) £16.18 108.550 (matching shares) £16.18 78.763 (matching shares) Aggregated information d) 981.116 Aggregated volume Price £16.18 2017-07-14 e) Date of the transaction Place of the transaction f) n/a 1. Details of PDMR/person closely associated with them ('PCA') Ms C Thomas

SVP, Human Resources

a) Name

b) Position/status

c)	Initial notification/ amendment	Initial no	otification	
2.	Details of the issuer, emission allowance market participant, auction platform,			
b)		5493000 e repeate	GlaxoSmithKline plc 5493000HZTVUYLO1D793 e repeated for (i) each type of instrument; te; and (iv) each place where transaction(s)	
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')		
b)	Nature of the transaction	ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 Jul 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonu Plan. Price(s) Volume(s)		
	Price(s) and volume(s)	£16.18		
		£16.18	158.805 (personal contribution)	
		£16.18	118.568 (personal contribution)	
		£16.18	78.002 (personal contribution)	
		£16.18	158.805 (personal contribution)	
a)		£16.18	118.568 (personal contribution)	
c)		£16.18	78.015 (matching shares)	
		£16.18	158.805 (matching shares)	
		£16.18	118.568 (matching shares)	
		£16.18	78.002 (matching shares)	
		£16.18	158.805 (matching shares)	
		£16.18	118.568 (matching shares)	
	Aggregated information			
d)	Aggregated volume Price	1,421.52 £16.18	1,421.526	
e)	Date of the transaction	2017-07-14		
f) Place of the transaction n/a				

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson

b) Position/status President, Global Affairs

Initial notification/ Initial notification amendment

Details of the issuer, emission allowance market participant, auction platform,

auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument;

3. (ii) each type of transaction; (iii) each date; and (iv) each place where

transaction(s) has been conducted

Ordinary shares of 25 pence each

('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the

b) Nature of the transaction

Company's 2009 Deferred Annual Bonus

Plan.

Price(s) Volume(s)

£16.18 52.988 (personal contribution)

£16.18 97.162 (personal contribution)

£16.18 74.644 (personal contribution)

c) Price(s) and volume(s)

£16.18 52.988 (matching shares)

£16.18 97.162 (matching shares)

£16.18 74.644 matching shares)

Aggregated information

d)

449.588 Aggregated volume Price £16.18 2017-07-14 e) Date of the transaction

Place of the transaction f) n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D E Troy

b) Position/status **SVP & General Counsel**

Initial notification/ Initial notification

amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

	Name LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793		
	Details of the transaction(s): section to b (ii) each type of transaction; (iii) each da	e repeated for (i) each type of instrument;		
a)	transaction(s) has been conducted Description of the financial instrument	America	an Depositary Shares ('ADSs')	
a)	Description of the imanetal institution	ISIN: US37733W1053 Increase in notional interest in ADSs		
b)	Nature of the transaction	paid to s ADSs he Deferred Price(s)	g the re-investment of dividends hareholders on 13 July 2017 on eld in the Company's 2009 I Annual Bonus Plan. Volume(s)	
	Price(s) and volume(s)	\$42.50	40.363 (personal contribution)	
		\$42.50	90.880 (personal contribution)	
		\$42.50	75.270 (personal contribution)	
		\$42.50	40.363 (personal contribution)	
		\$42.50	90.880 (personal contribution)	
c)		\$42.50	75.258 (personal contribution)	
C)		\$42.50	40.363 (matching shares)	
		\$42.50	90.880 (matching shares)	
		\$42.50	75.270 (matching shares)	
		\$42.50	40.363 (matching shares)	
		\$42.50	90.880 (matching shares)	
		\$42.50	75.258 (matching shares)	
	Aggregated information			
d)	Aggregated volume Price	826.028 \$42.50		
e)	Date of the transaction	2017-07-14		
f)	Place of the transaction	n/a		
1. a)	Details of PDMR/person closely associa Name	onted with them ('PCA') Dr P J T Vallance President, R&D		
b)	Position/status			

c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform,			
b)		GlaxoSmithKline plc 5493000HZTVUYLO1D793 e repeated for (i) each type of instrument; te; and (iv) each place where transaction(s)		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')		
b)	Nature of the transaction	ISIN: GB0009252882 Increase in notional interest in Ordinar Shares following the re-investment of dividends paid to shareholders on 13 Ju 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bon Plan. Price(s) Volume(s)		
		£16.18	114.838 (personal contribution)	
	Price(s) and volume(s)	£16.18	186.805 (personal contribution)	
		£16.18	128.784 (personal contribution)	
		£16.18	114.838 (personal contribution)	
		£16.18	186.805 (personal contribution)	
د.		£16.18	128.784 (personal contribution)	
C)		£16.18	114.838 (matching shares)	
		£16.18	186.805 (matching shares)	
		£16.18	128.784 (matching shares)	
		£16.18	114.838 (matching shares)	
		£16.18	186.805 (matching shares)	
		£16.18	128.784 (matching shares)	
	Aggregated information			
d)	Aggregated volume Price	1,721.70	98	
e)	Date of the transaction	£16.18 2017-07-14 n/a		
f)	Place of the transaction			

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: July 17, 2017

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc